Aion Therapeutic Hires CRO for Toppen Health; Announces Director Resignation
Aion Therapeutic (CSE: AION) has appointed Charles Freihofer as Chief Revenue Officer (CRO) of its water filtration subsidiary, Toppen Health. Freihofer, who joined in mid-September, brings over 20 years of experience in sales, marketing, and operations. In his previous role as President and CRO at Nvatomate, he achieved triple revenue growth and increased profit margins fivefold. The company also announced Larry Horwitz's resignation as director effective October 18, 2024, leaving the board with four directors.
Aion Therapeutic (CSE: AION) ha nominato Charles Freihofer come Chief Revenue Officer (CRO) della sua controllata per la filtrazione dell'acqua, Toppen Health. Freihofer, che è entrato in carica a metà settembre, porta con sé oltre 20 anni di esperienza in vendite, marketing e operazioni. Nel suo precedente ruolo di Presidente e CRO presso Nvatomate, ha ottenuto una crescita tripla dei ricavi e ha aumentato i margini di profitto di cinque volte. L'azienda ha anche annunciato le dimissioni di Larry Horwitz come direttore, a partire dal 18 ottobre 2024, lasciando il consiglio con quattro direttori.
Aion Therapeutic (CSE: AION) ha nombrado a Charles Freihofer como Chief Revenue Officer (CRO) de su filial de filtración de agua, Toppen Health. Freihofer, quien se unió a mediados de septiembre, trae consigo más de 20 años de experiencia en ventas, marketing y operaciones. En su rol anterior como Presidente y CRO en Nvatomate, logró un crecimiento de ingresos triple y aumentó los márgenes de beneficio cinco veces. La empresa también anunció la renuncia de Larry Horwitz como director a partir del 18 de octubre de 2024, dejando a la junta con cuatro directores.
Aion Therapeutic (CSE: AION)는 Charles Freihofer를 수처리 자회사인 Toppen Health의 최고 수익 책임자(CRO)로 임명했습니다. Freihofer는 9월 중순에 합류했으며, 판매, 마케팅 및 운영 분야에서 20년 이상의 경험을 가지고 있습니다. Nvatomate에서의 재직 시절, 그는 매출을 세 배로 성장시키고 수익률을 다섯 배로 증가시켰습니다. 회사는 또한 2024년 10월 18일부로 이사직을 그만두는 Larry Horwitz의 사임을 발표했으며, 이에 따라 이사회에는 네 명의 이사만 남게 됩니다.
Aion Therapeutic (CSE: AION) a nommé Charles Freihofer au poste de Chief Revenue Officer (CRO) de sa filiale de filtration d'eau, Toppen Health. Freihofer, qui a rejoint l'entreprise à la mi-septembre, apporte plus de 20 ans d'expérience en ventes, marketing et opérations. Dans son rôle précédent en tant que Président et CRO chez Nvatomate, il a réalisé une croissance des revenus triple et a augmenté les marges bénéficiaires par cinq. L'entreprise a également annoncé la démission de Larry Horwitz en tant que directeur, effective le 18 octobre 2024, laissant le conseil d'administration avec quatre directeurs.
Aion Therapeutic (CSE: AION) hat Charles Freihofer zum Chief Revenue Officer (CRO) seiner Wasserfiltrations-Tochtergesellschaft Toppen Health ernannt. Freihofer, der Mitte September an Bord kam, bringt über 20 Jahre Erfahrung in den Bereichen Vertrieb, Marketing und Betrieb mit. In seiner vorherigen Rolle als Präsident und CRO bei Nvatomate erzielte er ein dreifaches Umsatzwachstum und steigerte die Gewinnmargen um das Fünfzehnfache. Das Unternehmen gab außerdem die Rücktritt von Larry Horwitz als Direktor mit Wirkung zum 18. Oktober 2024 bekannt, wodurch der Vorstand nun aus vier Direktoren besteht.
- Appointment of experienced CRO with proven track record of revenue growth
- New CRO's previous success in tripling revenue and increasing profit margins fivefold at Nvatomate
- Strategic focus on revenue and earnings growth through new leadership
- Board director resignation reducing leadership team
Toronto, Ontario--(Newsfile Corp. - October 23, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company"), through its water filtration subsidiary, Toppen Health, Inc. ("Toppen" or "Toppen Health"), is excited to announce the appointment of Charles Freihofer as its new Chief Revenue Officer ("CRO"). Mr. Freihofer joined Toppen in mid-September to lead the organization's renewed focus on revenue and earnings. The Company is also announcing that Larry Horwitz resigned as a director effective Friday, October 18, 2024. The Company's board of directors currently consists of four directors.
With upwards of 20 years of experience in sales, marketing, and operational roles across a variety of industries, Mr. Freihofer has built a reputation for driving growth and scaling businesses through innovative strategies, customer-centric approaches, and strong team leadership.
"We're excited to have Charles on the Toppen team," said Owen Boyd, CEO of Toppen. "We started this company because we know water. We are water experts. With our established leading product portfolio, our need has become selecting the person we believe is best suited to lead our sales and growth efforts. Charles was the ideal candidate and it's a pleasure to welcome him to our team. Charles comes with a reputation for collaboration, versatility, and passion. He is a perfect fit and aligns well with Toppen's vision to bring clean, safe water to the masses."
Most recently, Mr. Freihofer served as President and CRO at Nvatomate, where he led the company to triple its revenue and increase profit margins fivefold. His success was driven by launching new products, implementing scalable business processes, and building strategic partnerships that enhanced the company's offerings and long-term sustainability.
Before Nvatomate, Mr. Freihofer founded and led Rebel Holdings, a network of companies focused on helping small and medium-sized businesses grow. Under his leadership, Rebel Holdings became the fastest-growing Independent Sales Organization ("ISO") in its space in the United States. Additionally, Mr. Freihofer has a history of excelling in high-growth environments, with key roles at companies such as Level 5 Advertising and Stag Parkway, where he signed record-breaking contracts and dramatically increased market share.
"It is an honour to join Toppen Health during this pivotal stage in their growth. Ensuring access to clean drinking water is not just a business goal but a moral imperative," Mr. Freihofer says. "I am excited to help scale our innovative water filtration solutions to reach communities and businesses in need worldwide."
A Future-Ready Approach to Water Filtration
With an emphasis on both innovation and accessibility, the Toppen team says Mr. Freihofer aims to entrench the company as a leader in the clean water movement. Toppen's patented technologies ensure that water filtration remains reliable, sustainable, and scalable for years to come.
About Aion Therapeutic Inc.
Aion Therapeutic is a forward-thinking business within the health and wellness sector with a diverse portfolio of intellectual property. With a commitment to innovation and transformative solutions, the Company is poised to drive positive change to redefine the boundaries of health and wellness.
Toppen, a wholly-owned subsidiary of Aion Therapeutic, is a US-based innovative health and wellness company dedicated to delivering state-of-the-art water filtration solutions. With a focus on innovation, affordability, and sustainability, Toppen's water filtration solutions are designed to meet the diverse needs of consumers, businesses, and industries around the world as they strive to provide access to clean and safe water.
For further information, please contact:
Aion Therapeutic Inc.
Graham Simmonds
Executive Chair & CEO
(416) 843-2881
DISCLAIMER & READER ADVISORY
This release contains forward-looking information within the meaning of applicable Canadian securities legislation. Expressions such as "anticipates", "expects", "believes", "estimates", "could", "intends", "may", "plans", "predicts", "projects", "will", "would" and other similar expressions, or the negative of these terms, are generally indicative of forward-looking information. Forward-looking statements in this press release include statements regarding: Toppen's business; Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied by such forward-looking information.
In addition, the forward-looking information contained in this release is based upon what management believes to be reasonable assumptions. Readers are cautioned not to place undue reliance on forward-looking information as it is inherently uncertain, and no assurance can be given that the expectations reflected in such information will prove to be correct. The forward-looking information in this release is made as of the date hereof and, except as required under applicable securities legislation, the Company assumes no obligation to update or revise such information to reflect new events or circumstances.
The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227472
FAQ
Who is the new Chief Revenue Officer of Aion Therapeutic's Toppen Health subsidiary?
What are Charles Freihofer's previous achievements before joining Aion Therapeutic (ANTCF)?
When did Larry Horwitz resign from Aion Therapeutic's board of directors?
